Please login to the form below

Not currently logged in
Email:
Password:

Pfizer completes $164m cash tender offer for Coley

Pfizer completes a cash tender offer to purchase all of the outstanding shares of US-based biopharmaceutical company, Coley Pharmaceutical

On 1 January 2008, Pfizer said it had completed a cash tender offer to purchase all of the outstanding shares of US-based biopharmaceutical company, Coley Pharmaceutical.

Pfizer said the $164m tender offer for Coley expired at midnight on 28 December 2007. The offer was not extended.

Pfizer said it has purchased close to 25 million shares of Coley common stock. The shares represent approximately 92.2 per cent of Coley's outstanding common stock, according to a Pfizer statement.

The world's largest pharmaceutical company plans to complete the merger in the coming days. Remaining Coley shareholders will receive the same $8.00 cash price per share paid in the tender offer, the release added.

Following the merger, Coley will become an indirect wholly owned subsidiary of Pfizer.

2nd January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics